ResearcherHunan Normal UniversityActive in the last 2 years

Wei Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4526-7900; OpenAlex author ID A5002902809. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2022: 2 papers · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Can… First author DOI 10.1002/cbdv.71778 ↗
Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection. Last author DOI 10.3389/fonc.2022.1074538 ↗
KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. Last author DOI 10.7150/jca.76695 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jing Li · 1 shared paper, 2026 · strength 0.43
- Paper Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity… DOI 10.1002/cbdv.71778 ↗
Peng Lin · 1 shared paper, 2026 · strength 0.43
- Paper Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity… DOI 10.1002/cbdv.71778 ↗
Manxiong Dai · 2 shared papers, 2022 · strength 0.37
- Paper KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. DOI 10.7150/jca.76695 ↗
- Paper Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection. DOI 10.3389/fonc.2022.1074538 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.